Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
RESEARCH TOOLSreports
Holding CVKD?
Track your performance easily
CVKD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.40 - $32.55
Previous Close$14.99
Volume113.00K
Average Volume (3M)58.87K
Market Cap
$24.86M
Enterprise Value$24.87M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$2.23K
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.30
Shares Outstanding1,658,771
10 Day Avg. Volume76,241
30 Day Avg. Volume58,869
Standard Deviation0.46
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)7.04
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-112.98
Enterprise Value/Ebitda-5.81
Forecast
1Y Price Target
$38.50Price Target Upside156.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cadrenal Therapeutics, Inc. News
PremiumCompany Announcements
Cadrenal Therapeutics Advances Tecarfarin Development
PremiumCompany Announcements
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin
PremiumCompany Announcements
Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $5.40 and its highest was $32.55 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Mar 17, 2025 which is in 113 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on Nov 07, 2024. The company reported -$2.181 earnings per share for the quarter, missing the consensus estimate of -$2.18 by >-$0.001.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 1,658,771 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$2.181 in its last earnings report, missing expectations of -$2.18. Following the earnings report the stock price went up 2.388%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
---
Cadrenal Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.50 (156.84% Upside)
$38.50 (156.84% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.3%
Last 30 Days ▲ 17.3%
Last 30 Days ▲ 17.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.22%
12-Months-Change
Fundamentals
Return on Equity
-125.15%
Trailing 12-Months
Asset Growth
-49.75%
Trailing 12-Months
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
---
CVKD Stock 12 Month Forecast
Average Price Target
$38.50
▲(156.84% Upside)
Technical Analysis
Achieve Life Sciences
―
Aclaris Therapeutics
―
Clearside Biomedical
―
Eton Pharmaceuticals
―
Best Analysts Covering CVKD
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+79.45%
reiterated a buy rating 17 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +79.45% per trade.
---